Anavex to present at Alzheimer’s Association International Conference on Alzheimer’s Disease
HOBOKEN, NJ, July 15, 2011 /PRNewswire/ – Anavex Life Sciences Corp. (“Anavex”)
(OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the
company’s lead compound for Alzheimer’s disease (AD) currently in Phase
I clinical trials, will be presented in two poster sessions at the 2011
Alzheimer’s Association International Conference on Alzheimer’s Disease
(AAICAD) in Paris, France.
Both ANAVEX 2-73 posters will be presented by Tangui Maurice, PhD, CNRS
Research Director, Team II Endogenous Neuroprotection in
Neurodegenerative Diseases INSERM, University of Montpellier.Â
Presentation details are as follows:
Date: Tuesday, July 19, 2011
Time: 12:30 - 3:00pm
Title: Preclinical development of new tetrahydrofuran derivatives
as neuroprotectants targeting the sigma-1 chaperone protein
Poster #: in Alzheimer's disease
P3-448
Date: Tuesday, July 19, 2011
Time: 12:30 - 3:00pm
Title: The novel tetrahydrofuran derivative ANAVEX 2-73 attenuated
GSK-3beta activation and Tau hyperphosphorylation in a
Poster #: nontransgenic Alzheimer's disease model in mice
16729
Note to editors: Pursuant to AAICAD policy, the abstracts for these
poster presentations cannot be disclosed until the formal presentations
have been made.
Any parties interested in meeting with the Anavex team at AAICAD may
contact the company’s communication’s team at +1 (416) 489-0092 or ir@anavex.com.
The 2011 Alzheimer’s Association International Conference on Alzheimer’s
Disease takes place July 16-21 in Paris, France. AAICAD is the world’s
premiere forum for reporting and discussion of groundbreaking research
and information on the cause, diagnosis, treatment and prevention of
Alzheimer’s disease and related disorders. Additional information
about the conference is available at http://www.alz.org/icad/overview.asp.
About the ANAVEX 2-73 Phase I Clinical Trial
This Phase I clinical trial is a randomized, placebo-controlled study to
initially test ANAVEX 2-73 as a single, ascending oral dose in healthy
male volunteers between the ages of 18 and 55. The trial seeks to
determine the maximum tolerated single dose, safety and
pharmacokinetics.
The Phase I clinical trial is being conducted in Germany in
collaboration with ABX-CRO, a clinical research organization that has
conducted several Alzheimer’s disease studies, and the Technical
University of Dresden.
About Alzheimer’s Disease
While Alzheimer’s disease is most common in people over the age of 65,
it can strike adults of any age irrespective of their gender,
background or socioeconomic status. According to the Alzheimer’s
Association, an estimated 5.4 million Americans are currently living
with Alzheimer’s disease. The number of Americans aged 65 and over with
Alzheimer’s is estimated to reach 7.7 million in 2030. This represents
a 50 percent increase from the 5.2 million Americans aged 65 and older
who are currently affected. The Alzheimer’s Association further
projects that the number of Americans aged 65 and older who are
affected by Alzheimer’s disease may double or triple to between 11 and
16 million by 2050 unless there are developments to prevent or more
effectively treat the disease.
About ANAVEX 2-73
ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs
being studied to potentially treat Alzheimer’s disease itself, versus
treating its symptoms.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a specialty pharmaceutical company engaged in the discovery and
development of novel drug candidates for the treatment of neurological
diseases and cancer. The Anavex proprietary SIGMACEPTOR(TM) Discovery
Platform involves the rational design of drug compounds targeted to
specific receptors involved in the modulation of multiple cellular
biochemical signaling pathways.
The SIGMACEPTOR(TM)-N program involves the development of novel drug
candidates that target neurological and neurodegenerative diseases
(Alzheimer’s disease, epilepsy, depression, pain). The company’s lead
drug candidates exhibit high affinity for sigma receptors, which have
been extensively documented as potentially valuable drug targets and
have demonstrated anti-amnesic and neuroprotective properties. A
portfolio of back-up compounds to ANAVEX 2-73 are also in development.
Anavex is a publicly traded company under the symbol AVXL.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Forward-looking statements in this
press release include that ANAVEX 2-73 is the first of a new class of
oral, disease-modifying drugs. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery and development, which include, without limitation, the
potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to retain key employees and our ability to
finance development or satisfy the rigorous regulatory requirements for
new drugs. Competitors may develop better or cheaper alternatives to
our products. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety
by this cautionary statement and Anavex Life Sciences Corp. undertakes
no obligation to revise or update this press release to reflect events
or circumstances after the date hereof.
Â
Anavex Life Sciences Corp.
Research & Business Development
Email:Â info@anavex.com
Shareholder & Media Relations
Toll-free: 1-866-505-2895
Outside North America: +1 (416) 489-0092
Email:Â ir@anavex.com
www.anavex.com
SOURCE Anavex Life Sciences Corp.